Literature DB >> 1394217

Time dependence of DNA lesions and growth inhibition by ICI D1694, a new quinazoline antifolate thymidylate synthase inhibitor.

M B Yin1, M A Guimaraes, Z G Zhang, M A Arredondo, Y M Rustum.   

Abstract

DNA single-strand breaks and associated growth inhibition induced by the thymidylate synthase inhibitor N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazoline-6-ylmethyl)-N -methylamino]-2 - thenoyl)-L-glutamic acid (ICI D1694) were quantitated using the human ileocecal adenocarcinoma cell line, HCT-8. The effects of different concentrations and schedules of [6R,S]-5-formyltetrahydrofolate ([6RS]LV) and 2'-deoxy-thymidine (dThd) on drug growth inhibition and DNA damage were also evaluated. The drug concentrations for 50% inhibition of cell growth in culture following 2-h and 72-h exposures were 0.073 and 0.003 microM, respectively. After a 2-h drug exposure, the occurrence of DNA single-strand breaks (SSBs) was time dependent. It was detectable at 8 h and reached a maximum at about 24 h, 34 +/- 3 (SD) and 305 +/- 34 rad equivalents with 0.1 microM (50% inhibition concentration) and 1.0 microM (90% inhibition concentration) ICI D1694, respectively. A significant level of DNA SSBs (101 +/- 13 rad equivalents) was still detectable at 72 h after the 2-h treatment with 1 microM ICI D1694. No significant level of DNA SSBs was detected when cells were exposed simultaneously to ICI D1694 and 20 microM [6RS]LV. Complete rescue of drug-induced DNA SSBs could be achieved when cells were exposed to 10 microM dThd starting no later than 4 h after drug treatment. The growth inhibition of ICI D1694 was abrogated by [6RS]LV in a concentration-dependent manner. Complete protection was achieved when cells were exposed simultaneously to 1 microM ICI D1694 and 5 microMs [6RS]LV or to 3 microMs dThd immediately after drug treatment. The results demonstrate that: (a) the growth inhibition of ICI D1694 is a function of time and schedule; (b) the growth inhibition is accompanied by extensive DNA single-strand breaks and slow repair; (c) at 1 microM ICI D1694, 3 microMs dThd and 5 microMs [6RS]LV can completely rescue cells from drug effects when dThd is added up to 4 h following drug treatment or when [6RS]LV is given in combination with the drug; (d) interference of [6RS]LV with ICI D1694 action may be occurring at the level of drug uptake and at intracellular targets, while dThd interferes with the drug action at intracellular targets.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394217

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients.

Authors:  Kong M Li; Laurent P Rivory; Janelle Hoskins; Rohini Sharma; Stephen J Clarke
Journal:  Br J Clin Pharmacol       Date:  2006-07-07       Impact factor: 4.335

2.  Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.

Authors:  William H Gmeiner; Jamie Jennings-Gee; Christopher H Stuart; Timothy S Pardee
Journal:  Leuk Res       Date:  2014-11-29       Impact factor: 3.156

3.  Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors.

Authors:  John C Schmitz; Edward Chu
Journal:  Silence       Date:  2011-01-19

4.  Resistance of a rodent malaria parasite to a thymidylate synthase inhibitor induces an apoptotic parasite death and imposes a huge cost of fitness.

Authors:  Francis W Muregi; Isao Ohta; Uchijima Masato; Hideto Kino; Akira Ishih
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

5.  Folate system correlations in DNA microarray data.

Authors:  Tomas Radivoyevitch
Journal:  BMC Cancer       Date:  2005-08-04       Impact factor: 4.430

6.  The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition.

Authors:  S D Webley; S J Welsh; A L Jackman; G W Aherne
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

7.  Raltitrexed increases radiation sensitivity of esophageal squamous carcinoma cells.

Authors:  Wen-Xiu Ding; Shu Liu; Jian-Xin Ma; Juan Pu; Hai-Jing Wang; Shu Zhang; Xin-Chen Sun
Journal:  Cancer Cell Int       Date:  2019-02-18       Impact factor: 5.722

8.  Clinical Outcomes of Drug-Eluting Bead Transarterial Chemoembolization Loaded with Raltitrexed for the Treatment of Unresectable or Recurrent Hepatocellular Carcinoma.

Authors:  Yonghua Bi; Dechao Jiao; Jianzhuang Ren; Xinwei Han
Journal:  Can J Gastroenterol Hepatol       Date:  2022-08-23

9.  Development of modified siRNA molecules incorporating 5-fluoro-2'-deoxyuridine residues to enhance cytotoxicity.

Authors:  Shao-yu Wu; Tian-min Chen; William H Gmeiner; Edward Chu; John C Schmitz
Journal:  Nucleic Acids Res       Date:  2013-02-28       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.